MedTrace Logo

INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD

NCT01016873 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2014-12-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to confirm the safety and establish the effectiveness of two doses from the IRay System for the treatment of wet AMD.

Conditions

Interventions

DEVICE

IRay

Low voltage stereotactic radiotherapy system

Sponsors & Collaborators

  • Oraya Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Denis O'Shaughnessy, Ph.D. · Oraya Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2012-05-31
Completion
2014-04-30

Countries

  • Austria
  • Czechia
  • Germany
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01016873 on ClinicalTrials.gov